LOL! No one in their right mind would approve or pay $200k for anything beyond GBM. Just look at UK. They can’t even find a dozen self paying GBM patients per year where they competed a phase 3 trial with data published in JAMA many years ago. Such BS!
Market Data 
Markets 
